scispace - formally typeset
Search or ask a question
Author

Behzad Hajarizadeh

Bio: Behzad Hajarizadeh is an academic researcher from Kirby Institute. The author has contributed to research in topics: Hepatitis C & Hepatitis C virus. The author has an hindex of 36, co-authored 152 publications receiving 7083 citations. Previous affiliations of Behzad Hajarizadeh include Joint United Nations Programme on HIV/AIDS & Tehran University of Medical Sciences.


Papers
More filters
Journal ArticleDOI
Sarah Blach1, Stefan Zeuzem, Michael Manns, Ibrahim Altraif  +218 moreInstitutions (6)
TL;DR: The global estimate of viraemic HCV infections is lower than previous estimates, largely due to more recent prevalence estimates in Africa, and increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections.

1,578 citations

Journal ArticleDOI
TL;DR: The estimate of HBV prevalence in 2016 differs from previous studies, potentially because it took into account the effect of infant prophylaxis and early childhood vaccination, as well as changing prevalence over time.

1,145 citations

Journal ArticleDOI
TL;DR: Differences in past HCV incidence and current HCV prevalence, together with the generally protracted nature of HCV disease progression, has led to considerable diversity in the burden of advanced liver disease in different countries.
Abstract: Worldwide, an estimated 130-170 million people have HCV infection. HCV prevalence is highest in Egypt at >10% of the general population and China has the most people with HCV (29.8 million). Differences in past HCV incidence and current HCV prevalence, together with the generally protracted nature of HCV disease progression, has led to considerable diversity in the burden of advanced liver disease in different countries. Countries with a high incidence of HCV or peak incidence in the recent past will have further escalations in HCV-related cirrhosis and hepatocellular carcinoma (HCC) over the next two decades. Acute HCV infection is difficult to detect because of the generally asymptomatic nature of the disease and the marginalization of at-risk populations. Around 25% of patients with acute HCV infection undergo spontaneous clearance, with increased rates among those with favourable IL28B genotypes, acute symptoms and in women. The remaining 75% of patients progress to chronic HCV infection and are subsequently at risk of progression to hepatic fibrosis, cirrhosis and HCC. Chronic hepatitis C generally progresses slowly in the initial two decades, but can be accelerated during this time as a result of advancing age and co-factors such as heavy alcohol intake and HIV co-infection.

885 citations

Journal ArticleDOI
A. Sibley, Kwang Hyub Han1, A. Abourached, Laurentius A. Lesmana2, Mihály Makara, Wasim Jafri3, Riina Salupere4, Abdullah M. Assiri, Adrian Goldis, Faisal Abaalkhail5, Zaigham Abbas6, A. Abdou7, F. Al Braiki, F. Al Hosani, K. Al Jaberi, M. Al Khatry, M. A. Al Mulla, H. Al Quraishi7, A. Al Rifai, Y. Al Serkal, Altaf Alam8, Seyed Moayed Alavian9, Hamad I. Al-Ashgar5, S. Alawadhi7, L. Al-Dabal7, P. Aldins, Faleh Z. Al-Faleh10, Abdullah S. Alghamdi, R. Al-Hakeem, Abdulrahman Aljumah11, A. Almessabi, Adel Alqutub, Khalid Alswat10, Ibrahim Altraif11, M. Alzaabi, N. Andrea, Mohamed A. Babatin, A. Baqir, M. T. Barakat, Ottar M. Bergmann, Abdul Rahman Bizri12, Sarah Blach, Asad Chaudhry, M. S. Choi13, T. Diab, Samsuridjal Djauzi2, E. S. El Hassan7, S. El Khoury14, Chris Estes, S. Fakhry, J. I. Farooqi15, J. I. Farooqi16, H. Fridjonsdottir17, Rino Alvani Gani2, A. Ghafoor Khan16, Liana Gheorghe, Magnus Gottfredsson18, S. Gregorcic19, Jessie Gunter, Behzad Hajarizadeh20, Behzad Hajarizadeh21, Saeed Hamid3, Irsan Hasan2, Almoutaz Hashim5, Gabor Horvath, Béla Hunyady22, R. Husni23, Agita Jeruma, Jon G. Jonasson24, Jon G. Jonasson17, B. Karlsdottir, Do Young Kim1, Young Seok Kim25, Z. Koutoubi26, Valentina Liakina27, Valentina Liakina28, Young-Suk Lim29, A. Löve18, A. Löve24, Matti Maimets4, Reza Malekzadeh30, Mojca Maticic19, Muhammad S. Memon31, Shahin Merat30, Jacques E Mokhbat23, Fadi H. Mourad12, David H. Muljono32, David H. Muljono33, Arif Nawaz34, N. Nugrahini, S. Olafsson, S. Priohutomo, H. Qureshi35, P. Rassam14, Homie Razavi, Devin Razavi-Shearer, Kathryn Razavi-Shearer, Baiba Rozentale, M. Sadik31, K. Saeed, A. Salamat36, Faisal M. Sanai10, A. Sanityoso Sulaiman2, R. A. Sayegh37, Ala I. Sharara12, M. Siddiq34, A. M. Siddiqui38, G. Sigmundsdottir, B. Sigurdardottir, Danute Speiciene28, Andri Sanityoso Sulaiman2, Marwa Sultan, M. Taha, Junko Tanaka39, H. Tarifi, G. Tayyab40, Ieva Tolmane, M. Ud Din, M. Umar41, M. Umar2, M. Umar42, Jonas Valantinas28, J. Videčnik-Zorman19, Cesar Yaghi37, Evy Yunihastuti2, M. A. Yusuf34, Bader Faiyaz Zuberi43, Jonathan Schmelzer 
TL;DR: The current treatment rate and efficacy are not sufficient to manage the disease burden of hepatitis C virus and alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver‐related deaths from increasing.
Abstract: The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.

463 citations

Journal ArticleDOI
TL;DR: A meta-analysis to compare occurrence and recurrence of HCC in patients receiving either DAA or interferon (IFN) therapy found there is no evidence that HCC occurrence or recurrence is different between patients receiving DAA and IFN therapy.

387 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.

7,851 citations

Journal ArticleDOI
TL;DR: The optimal management of patients with acute and chronic HCV infections in 2018 and onwards is described, as well as developments in diagnostic procedures and improvements in therapy and prevention.

2,491 citations

Journal ArticleDOI
TL;DR: This paper aims to demonstrate the efforts towards in-situ applicability of EMMARM, as to provide real-time information about concrete mechanical properties such as E-modulus and compressive strength.

2,416 citations

Journal ArticleDOI
TL;DR: Together, rational deployment of prevention, attainment of global goals for viral hepatitis eradication, and improvements in HCC surveillance and therapy hold promise for achieving a substantial reduction in the worldwide HCC burden within the next few decades.
Abstract: Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol addiction, metabolic liver disease (particularly nonalcoholic fatty liver disease) and exposure to dietary toxins such as aflatoxins and aristolochic acid. All these risk factors are potentially preventable, highlighting the considerable potential of risk prevention for decreasing the global burden of HCC. HCC surveillance and early detection increase the chance of potentially curative treatment; however, HCC surveillance is substantially underutilized, even in countries with sufficient medical resources. Early-stage HCC can be treated curatively by local ablation, surgical resection or liver transplantation. Treatment selection depends on tumour characteristics, the severity of underlying liver dysfunction, age, other medical comorbidities, and available medical resources and local expertise. Catheter-based locoregional treatment is used in patients with intermediate-stage cancer. Kinase and immune checkpoint inhibitors have been shown to be effective treatment options in patients with advanced-stage HCC. Together, rational deployment of prevention, attainment of global goals for viral hepatitis eradication, and improvements in HCC surveillance and therapy hold promise for achieving a substantial reduction in the worldwide HCC burden within the next few decades.

2,122 citations

Journal Article
TL;DR: Qualitative research in such mobile health clinics has found that patients value the informal, familiar environment in a convenient location, with staff who “are easy to talk to,” and that the staff’s “marriage of professional and personal discourses” provides patients the space to disclose information themselves.
Abstract: www.mobilehealthmap.org 617‐442‐3200 New research shows that mobile health clinics improve health outcomes for hard to reach populations in cost‐effective and culturally competent ways . A Harvard Medical School study determined that for every dollar invested in a mobile health clinic, the US healthcare system saves $30 on average. Mobile health clinics, which offer a range of services from preventive screenings to asthma treatment, leverage their mobility to treat people in the convenience of their own communities. For example, a mobile health clinic in Baltimore, MD, has documented savings of $3,500 per child seen due to reduced asthma‐related hospitalizations. The estimated 2,000 mobile health clinics across the country are providing similarly cost‐effective access to healthcare for a wide range of populations. Many successful mobile health clinics cite their ability to foster trusting relationships. Qualitative research in such mobile health clinics has found that patients value the informal, familiar environment in a convenient location, with staff who “are easy to talk to,” and that the staff’s “marriage of professional and personal discourses” provides patients the space to disclose information themselves. A communications academic argued that mobile health clinics’ unique use of space is important in facilitating these relationships. Mobile health clinics park in the heart of the community in familiar spaces, like shopping centers or bus stations, which lend themselves to the local community atmosphere.

2,003 citations